Walter Noordzij
dr.
In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.
[18F]F-FAPI PET/CT and LAparoscopy in STagIng advanced gastric Cancer: a multicenter prospective study (PLASTIC-3 study).
Published in: BMC Cancer
Access to document
10.1186/s12885-025-15347-7
BACKGROUND: Treatment decisions for locally advanced gastric adenocarcinoma rely on staging with gastroscopy, computed tomography (CT), and staging laparoscopy (SL). However, CT often fails to detect peritoneal and other distant metastases, and SL is an invasive procedure with complication risks and costs. Therefore, an accurate non-invasive imaging biomarker to detect such metastases could improve the care for gastric cancer patients. Radiolabeled fibroblast-activating protein inhibitors (FAPI), targeting stromal cancer-associated fibroblasts, are promising radiotracers. Preliminary Asian studies indicate that FAPI PET/CT outperforms [ 18F]FDG PET/CT in tracer uptake, tumor-to-background ratio...
PLASTIC-3 Study Group, Lianne Triemstra, Sarah W J M Spruijt, Dennis Vriens, Erik Vegt, Wilma E Mesker, Luuk J A C Hawinkels, Sopany Saing, Marije Slingerland, Vera Kemp, Stijn A L P Crobach, Jelle J Goeman, Martin Pool, Petra Dibbets-Schneider, Roel J Bennink, Mark I van Berge Henegouwen, Marc J van Det, Boudewijn J van Etten, Henk H Hartgrink, Richard van HillegersbergMarnix G E H Lam, Nanda M Smulders, Misha D P Luyer, Walter Noordzij, Emilia C Owers, Wim J G Oyen, Johanna W van Sandick, Wendy Schreurs, Wobbe O de Steur, Jan H M B Stoot, Leo E Weijs, Bas P L Wijnhoven, Bart P L Witteman, Jelle P Ruurda, Lioe-Fee de Geus-Oei
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document
10.1038/s41467-025-66767-9
document
Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8 + T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8 + T-cells. Therefore, we conducted an exploratory phase 2 single-arm trial utilizing a zirconium-89-labeled one-armed anti-CD8α antibody ( 89ZED88082A) to enable whole-body imaging of CD8 + T-cells through positron emission tomography (PET) (NL9034; EUCTR2020-004749-35-NL). Imaging analysis was performed in 23 patients...
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten
Influence of Ultra-Low-Dose CT on PET Image Quantification and Visual Assessment
Published in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Access to document
10.2967/jnumed.124.269188
Recent advances in high-sensitivity PET allow for significantly reduced radiation doses, making the CT radiation dose a larger fraction of the total scan dose. This is the first study to the best of our knowledge that evaluates the feasibility and efficacy of an ultra-low-dose CT (ULD-CT) protocol, incorporating a Sn filter, by reducing radiation exposure while maintaining PET image quality and quantitative accuracy in oncology patients. Methods: The study involved 29 oncology patients. FDG PET/CT scans were performed using both low-dose CT (LD-CT) and ULD-CT protocols. The ULD-CT...
Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatment
Published in: Virchows Archiv : an International Journal of Pathology
Access to document
10.1007/s00428-025-04269-1
document
A 59-year-old woman with two colorectal adenocarcinomas in 2015 and 2022 (both with loss of MSH2 and focal presence of MSH6 protein, thus MMR-deficient profile) had a variant of c.1012G > C p.(Gly338Arg) in the MSH2 gene, classified as Variant of Uncertain Significance (VUS) in 2023. That year, she was also diagnosed with oesophageal squamous cell carcinoma (ESCC), again MMR-deficient. Although uncommon, a proportion of ESCC can be MMR-deficient. The ESCC showed complete response to nivolumab. Genetic studies of the three tumours showed the same germline variant. During follow-up, the...
H H Wang, G Kats-Ugurlu, R H Sijmons, J L Kluiver, S Z Commandeur-Jan, W Noordzij, B van Etten, J T M Plukker, G A P Hospers, D G Knapen
Financial illiteracy among internal medicine, surgery, and radiology residents regarding medical imaging costs in the Netherlands
Published in: European Radiology
Access to document
10.1007/s00330-025-11510-7
document
PURPOSE: To assess the knowledge of internal medicine, surgery, and radiology residents of medical imaging costs at a university hospital in the Netherlands. METHODS: A survey was conducted among internal medicine, surgery, and radiology residents at a tertiary care university hospital to determine their knowledge and view on medical imaging costs. Participants were asked to estimate the costs of a two-view chest X-ray, unenhanced CT of the brain, unenhanced MRI of the brain, contrast-enhanced CT of the chest and abdomen, ultrasound of the complete abdomen, and FDG-PET and...